Efpeglenatide vs Semaglutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicEfpeglenatideSemaglutide
What it is

An exendin-4 analogue linked by polyethylene glycol to a human IgG4 Fc fragment, also coded HM11260C, according to FDA’s substance registry.1

A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.4

FDA status

In clinical trials

In clinical trials; not FDA-approved1,2,3

Not FDA-approved. No FDA approval is reported in the sources reviewed here, and a phase 3 trial in type 2 diabetes is registered as recruiting.1,2

Is efpeglenatide FDA-approved?

FDA-approved

FDA-approved as Ozempic, Rybelsus and Wegovy4,5,6,7

FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.4,5,6,7

Is semaglutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.8

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Efpeglenatide is not among them.8,9

Not among the six peptides the policy lists.8

FDA compounding safety-risk page

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list efpeglenatide.3

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial AMPLITUDE-O (NCT03496298): a randomized, placebo-controlled trial at 344 sites in 28 countries in 4,076 participants with type 2 diabetes and cardiovascular or kidney disease, in which major cardiovascular events occurred in 7.0% on efpeglenatide and 9.2% on placebo.10

Large randomized human trials

  • Large randomized human trial A double-blind, placebo-controlled cardiovascular trial (NCT03574597) that randomized 17,604 adults aged 45 or older with established cardiovascular disease and obesity or overweight, without diabetes. The label reports a hazard ratio of 0.80 for major adverse cardiovascular events.4
  • Large randomized human trial A 68-week randomized, double-blind, placebo-controlled weight trial (NCT03548935) in 1,961 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes. It is one of several weight trials the label describes.4
  • Large randomized human trial A randomized, double-blind, placebo-controlled MASH trial (NCT04822181) whose week-72 analysis included 800 adults with moderate to advanced liver fibrosis.4
Records collected

6 ClinicalTrials.gov records and 1 PubMed record collected

140 ClinicalTrials.gov records and 108 PubMed records collected

Area of study

Metabolic and weight, Heart and blood vessels10

Metabolic and weight, Heart and blood vessels, Liver4

Latest dated events
  1. The AMPLITUDE-O trial of efpeglenatide in 4,076 adults with type 2 diabetes is published.10
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.11
  2. DailyMed publishes the Wegovy label version cited on this page.4
  3. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.12

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Efpeglenatide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    ClinicalTrials.gov record NCT07379333 · retained source version 2026-05-13:c599578eaa8d429e0152e13caf981fed9266ac8441a80524f20f68e1f1aaac63 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  5. 5
    Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  10. 10
    Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes (2021) · PMID 34215025 ↗

    The New England Journal of Medicine · Official source · Source checked November 16, 2026

  11. 11
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  12. 12
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026